Search Results - "Miguel, Ramón San"

Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C by San Miguel, Ramón, Gimeno-Ballester, Vicente, Blázquez, Antonio, Mar, Javier

“…A new scenario of therapy for chronic hepatitis C (CHC) is being established with the approval of sofosbuvir (SOF). To estimate the cost-effectiveness of…”
Get more information

Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population by Juanbeltz, Regina, Castilla, Jesús, Martínez-Baz, Iván, O’Leary, Aisling, Sarobe, Maite, Miguel, Ramón San

“…Purpose To compare health-related quality of life (HRQoL) between hepatitis C patients who achieve sustained virological response (SVR) to direct-acting…”
Get full text

Clinical course of patients with severe COVID-19 pneumonia treated with remdesivir: A real-life study by Tejada, Diana, Juanbeltz, Regina, Rivero, María, San Miguel, Ramón, Capdevila, Ferrán, Beloqui, Juan José, Sarobe, Maite

“…There is currently much uncertainty regarding the most optimal treatment for COVID-19. This study analyze the change in the clinical condition of patients…”
Get full text

Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients by Juanbeltz, Regina, Martínez-Baz, Iván, San Miguel, Ramón, Goñi-Esarte, Silvia, Cabasés, Juan Manuel, Castilla, Jesús

“…Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve sustained virological response (SVR) in chronic hepatitis C patients. We aim to…”
Get full text

Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain by Juanbeltz, Regina, Pérez-García, Alejandra, Aguinaga, Aitziber, Martínez-Baz, Iván, Casado, Itziar, Burgui, Cristina, Goñi-Esarte, Silvia, Repáraz, Jesús, Zozaya, José Manuel, San Miguel, Ramón, Ezpeleta, Carmen, Castilla, Jesús

“…The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed…”
Get full text

Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients by Blázquez-Pérez, Antonio, San Miguel, Ramón, Mar, Javier

“…Background Chronic hepatitis C is the leading cause of chronic liver disease, representing a significant burden in terms of morbidity, mortality and costs. A…”
Get full text

Recapture of patients with an incomplete diagnosis of hepatitis C virus infection by Burgui, Cristina, Martín, Carmen, Juanbeltz, Regina, San Miguel, Ramón, Martínez-Baz, Iván, Zozaya, José Manuel, Castilla, Jesús

“…Background: hepatitis C virus (HCV) antibody tests have been performed since the 90s, although HCV-RNA (viral load) determination was not always performed…”
Get full text

Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents by Goñi Esarte, Silvia, Juanbeltz, Regina, Martínez-Baz, Iván, Castilla, Jesús, San Miguel, Ramón, Herrero, José Ignacio, Zozaya, José Manuel

“…new direct-acting antivirals (DAAs) achieve high and sustained virological response (SVR) rates, although the long-term effect on patient health-related…”
Get full text

Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals by Mar, Javier, Ibarrondo, Oliver, Martínez-Baz, Iván, Juanbeltz, Regina, San Miguel, Ramón, Casado, Itziar, Arrospide, Arantzazu, Castilla, Jesús

“…The high initial cost of antivirals against hepatitis C prompted development of the "Strategic Plan for Tackling Chronic Hepatitis C in the Spanish National…”
Get full text

Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016 by Fontela, Carmen, Castilla, Jesús, Juanbeltz, Regina, Martínez-Baz, Iván, Rivero, María, O'Leary, Aisling, Larrea, Natalia, San Miguel, Ramón

“…The increased survival of HIV-infected individuals has resulted in a premature aging of this population, with the consequent development of premature…”
Get full text

Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy by Reina, Elena, San Miguel, Ramón, Larrea, Natalia, Garcia, Patricia, Napal, Victor

“…Background Previous studies have evaluated the simplification of HIV treatment with ritonavir-boosted protease inhibitor monotherapy, demonstrating acceptable…”
Get full text

Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population by Fontela, Carmen, Aguinaga, Aitziber, Moreno-Iribas, Conchi, Repáraz, Jesús, Rivero, María, Gracia, María, Floristán, Yugo, Fresán, Ujué, Miguel, Ramón San, Ezpeleta, Carmen, Castilla, Jesús

“…Combination antiretroviral therapy reduces mortality of HIV-infected persons. In Spain, where this therapy is widely available, we aim to evaluate mortality…”
Get full text

Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal by Burgui, Cristina, San Miguel, Ramón, Goñi-Esarte, Silvia, Juanbeltz, Regina, Úriz-Otano, Juan Isidro, Reparaz, Jesús, Sarobe, Maite, Zozaya, José Manuel, Castilla, Jesús

“…Second-generation direct-acting antivirals (DAAs) have shown high efficacy in the treatment of chronic hepatitis C virus (HCV) infections in clinical trials…”
Get full text

Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients by Gimeno-Ballester, Vicente, Mar, Javier, O'Leary, Aisling, Adams, Róisín, San Miguel, Ramón

“…This study provides a cost-effectiveness analysis of therapeutic strategies for chronic hepatitis C genotype 3 infected patients in Spain. A Markov model was…”
Get more information

Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis by Mar, Javier, Mar-Barrutia, Lorea, Gimeno-Ballester, Vicente, San Miguel, Ramón

“…The aim of this study was to measure the cost-effectiveness of the treatment with simeprevir and sofosbuvir in chronic hepatitis C genotype 1 patients with…”
Get full text

Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C by Gimeno-Ballester, Vicente, Mar, Javier, San Miguel, Ramón

“…The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. To estimate the…”
Get more information

Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments by Mar, Javier, Martínez-Baz, Iván, Ibarrondo, Oliver, Juanbeltz, Regina, San Miguel, Ramón, Casado, Itziar, O'Leary, Aisling, Castilla, Jesús

“…: The aim of this study was to describe the natural long-term course of end-stage liver disease associated with chronic hepatitis C (HCV) infection by…”
Get more information

Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions by Juanbeltz, Regina, Goñi Esarte, Silvia, Úriz-Otano, Juan Isidro, Martínez Echeverría, Ana, Elizalde, Inmaculada, Zozaya, José Manuel, Castilla, Jesús, San Miguel, Ramón

“…Objectives: Direct acting antivirals (DAA) are extremely effective to treat chronic hepatitis C. The aim of this study was to evaluate, by using objective…”
Get full text

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence by Gimeno-Ballester, Vicente, Simón, Miguel Ángel, Trigo, Cristina, Mar, Javier, San Miguel, Ramón

“…Sofosbuvir (SOF) with simeprevir (SIM) combination was the first interferon-free regimen that reached optimal results in terms of sustained viral response…”
Get more information

Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature by San Miguel, Ramón, Gimeno-Ballester, Vicente, Mar, Javier

“…The treatment of chronic hepatitis C has experienced a substantial progress with the arrival of Boceprevir and Telaprevir due to the significant increase in…”
Get more information